Armor CAR T Cells with Enhanced Potency for Cancer Immunotherapy

Join Agilent and leading researchers as they share how they're navigating complex biology, exploring new scientific galaxies, and charting pathways to breakthrough therapies. From unlocking cellular mysteries to uncovering molecular insights, discover how today's innovations are helping propel research toward its next giant leap.

All attendees with be automatically entered into a drawing to win a FREE Tablet!

Part 4: Armor CAR T Cells with Enhanced Potency for Cancer Immunotherapy

The success of CAR T cell immunotherapy depends on the differentiation status and metabolic fitness of the CAR T cell product. Our research challenges conventional CAR T cell therapy protocols by demonstrating that functional CAR T cells can be rapidly generated within 24 hours without the need for activation or ex vivo expansion, preserving their maximal fitness. By harnessing the intrinsic stemness of non-activated CAR T cells and co-expressing specific cytokines to enhance anti-tumor efficacy, we aim to elevate metabolic and effector functions, thereby improving long-term persistence and therapeutic impact. These findings offer promising avenues to enhance the efficacy and accessibility of CAR T cell therapy for cancer patients.

Presenter: Saba Ghassemi, PhD (Assistant professor, Center for Cellular Immunotherapies, University of Pennsylvania)